Since our arrival in Canada in 1972 Boehringer Ingelheim has played a varied and integral role in the health of Canadians. We are committed to finding medical breakthroughs and investing in research, development and medicine for therapies which fulfill unmet medical needs.
Through our participation in medical and pharmaceutical research, both in Canada and worldwide, we have contributed to significant improvements in healthcare and developed innovative and cost-effective medicines. We have earned a reputation as a leader in the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD), and have broadened the scope of our work to include diseases such as hypertension, stroke, arthritis, benign prostatic hyperplasia (BPH), Parkinson’s disease and HIV/AIDS.
Participant in Dermatology Update 2021 SPRING Virtual Meeting:
05jun11:15 am12:15 pmMoved OnlineUpdate on Pustular Psoriasis: Current Approaches to Management and Emerging Opportunities to Improve Patient CareBoehringer Ingelheim Open SessionSpeakers: Dr. Melinda Gooderham, Dr. Kim Papp | Moderator: Dr. Sam Hanna11:15 am - 12:15 pm(GMT-04:00) View in my time Event Organized By: Boehringer Ingelheim